---
figid: PMC5977747__13073_2018_546_Fig2_HTML
figlink: /pmc/articles/PMC5977747/figure/Fig2/
number: F2
caption: 'Possible scenarios for PanDrugs therapeutic candidates. PanDrugs proposes
  three potential types of druggable candidates. This includes: (1) direct targets,
  a gene that contributes to a disease phenotype and can be directly targeted by a
  drug; (2) drug-resistance biomarkers, a gene which genetic status is associated
  with a drug response from clinical or pre-clinical evidence but its protein product
  is not the direct target of the drug; and (3) pathway members, a targetable gene
  located downstream to the altered one. To illustrate this, tumors mutated in EGFR
  carrying MET amplifications will not respond to EGFR inhibitors (red). PanDrugs
  proposes as therapeutic strategy MET inhibitors and targeting MET downstream proteins
  (green) to drive tumor cell death'
pmcid: PMC5977747
papertitle: 'PanDrugs: a novel method to prioritize anticancer drug treatments according
  to individual genomic data.'
reftext: Elena Piñeiro-Yáñez, et al. Genome Med. 2018;10:41.
pmc_ranked_result_index: '6600'
pathway_score: 0.95772
filename: 13073_2018_546_Fig2_HTML.jpg
figtitle: Possible scenarios for PanDrugs therapeutic candidates
year: '2018'
organisms:
- Homo sapiens
ndex: 45bc5768-ded6-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5977747__13073_2018_546_Fig2_HTML.html
  '@type': Dataset
  description: 'Possible scenarios for PanDrugs therapeutic candidates. PanDrugs proposes
    three potential types of druggable candidates. This includes: (1) direct targets,
    a gene that contributes to a disease phenotype and can be directly targeted by
    a drug; (2) drug-resistance biomarkers, a gene which genetic status is associated
    with a drug response from clinical or pre-clinical evidence but its protein product
    is not the direct target of the drug; and (3) pathway members, a targetable gene
    located downstream to the altered one. To illustrate this, tumors mutated in EGFR
    carrying MET amplifications will not respond to EGFR inhibitors (red). PanDrugs
    proposes as therapeutic strategy MET inhibitors and targeting MET downstream proteins
    (green) to drive tumor cell death'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3R6
  - AKT1
  - AKT3
  - PIK3R3
  - ARAF
  - PIK3CG
  - MTOR
  - HRAS
  - RAF1
  - BRAF
  - AKT2
  - EGF
  - KRAS
  - NRAS
  - MAPK1
  - MAPK3
  - HGF
  - MAP2K1
  - MAP2K2
  - MET
  - PIK3R4
  - PIK3CA
  - PIK3CD
  - PIK3R5
  - PIK3CB
  - EGFR
  - Erlotinib
  - Gefitinib
  - Afatinib
  - Crizotinib
  - Carbozantinib
  - Sorafenib
  - Regorafenib
  - Trametinib
  - Cobimetinib
  - Bosutinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: HGF
  symbol: HGF
  source: hgnc_symbol
  hgnc_symbol: HGF
  entrez: '3082'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: EGF-R
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
chemicals:
- word: Erlotinib
  source: MESH
  identifier: C400278
- word: Gefitinib
  source: MESH
  identifier: C419708
- word: Afatinib
  source: MESH
  identifier: C522924
- word: Crizotinib
  source: MESH
  identifier: C551994
- word: Carbozantinib
  source: ''
  identifier: ''
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: Regorafenib
  source: MESH
  identifier: C559147
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Cobimetinib
  source: MESH
  identifier: C574276
- word: Bosutinib
  source: MESH
  identifier: C471992
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC5977747__F2
redirect_from: /figures/PMC5977747__F2
figtype: Figure
---
